64036-07-3 Usage
Uses
Used in Pharmaceutical Industry:
(4S)-3-(1,3-benzodioxol-5-yl)-6,7-dimethoxy-2-methyl-1-oxo-1,2,3,4-tetrahydroisoquinoline-4-carboxylic acid is used as a potential pharmaceutical compound for its unique structure and functional groups. The presence of the carboxylic acid group may allow for interactions with various biological targets, potentially leading to the development of new drugs.
Used in Chemical Research:
In the field of chemical research, (4S)-3-(1,3-benzodioxol-5-yl)-6,7-dimethoxy-2-methyl-1-oxo-1,2,3,4-tetrahydroisoquinoline-4-carboxylic acid can be used as a starting material or a building block for the synthesis of more complex molecules. Its unique structure may provide new insights into the design and synthesis of novel compounds with specific properties and applications.
Used in Material Science:
(4S)-3-(1,3-benzodioxol-5-yl)-6,7-dimethoxy-2-methyl-1-oxo-1,2,3,4-tetrahydroisoquinoline-4-carboxylic acid's structural features, including the benzodioxol and tetrahydroisoquinoline rings, may offer potential applications in material science. It could be explored for its properties in areas such as organic electronics, where its electronic and structural characteristics could be harnessed for the development of new materials with specific functionalities.
Check Digit Verification of cas no
The CAS Registry Mumber 64036-07-3 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 6,4,0,3 and 6 respectively; the second part has 2 digits, 0 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 64036-07:
(7*6)+(6*4)+(5*0)+(4*3)+(3*6)+(2*0)+(1*7)=103
103 % 10 = 3
So 64036-07-3 is a valid CAS Registry Number.
64036-07-3Relevant academic research and scientific papers
Synthesis and biological activity of structural analogues of the anticancer benzophenanthridine alkaloid nitidine chloride
Cushman,Mohan,Smith
, p. 544 - 547 (2007/10/02)
The indenoisoquinoline analogue 9 of nitidine (1) has been prepared and found to possess significant anticancer activity against L1210 lymphoid leukemia, P388 lymphocytic leukemia, and B16 melanocarcinoma. Analogue 14, which lacks the B ring of nitidine (1), has also been synthesized. Compound 14 retains the in vitro toxicity associated with nitidine (1) but is devoid of antileukemic activity. The structural factors that may contribute to the difference in biological activity between the two closely related analogues 9 and 14 are discussed.
